3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Acrocephalosyndactylia
5
Cholangiocarcinoma
3
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Stomach Neoplasms
1
Recurrence
1
Oligodendroglioma
1
Neoplasms, Unknown Primary
1
Multiple Myeloma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Eosinophilia
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Malignancies
1
Interventions
Temozolomide
47
Bevacizumab
41
Radiotherapy
17
Magnetic Resonance Spectroscopy
14
Irinotecan
11
Nivolumab
8
Everolimus
7
Radiation
6
poly ICLC
5
X-Rays
5
Phantoms, Imaging
5
Carboplatin
5
pembrolizumab
4
fluorodopa F 18
4
Specimen Handling
4
Nuclear Medicine Department, Hospital
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Erlotinib Hydrochloride
4
Carmustine
4
ribociclib
3
palbociclib
3
ivosidenib
3
antineoplaston A10
3
Vorinostat
3
Radiotherapy, Intensity-Modulated
3
Radiosurgery
3
Modafinil
3
Lomustine
3
Biopsy
3
veliparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Glioma
×
pemigatinib
×
Clear all
NCT05267106
2025-12-30
FIGHT-209
Incyte Corporation
Phase 2
Terminated
83 enrolled
18 charts